Skip to main content
SINSIN PHARMACEUTICAL Co., LTD. logo

SINSIN PHARMACEUTICAL Co., LTD. — Investor Relations & Filings

Ticker · 002800 ISIN · KR7002800001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country KR South Korea
Listing KO 002800

About SINSIN PHARMACEUTICAL Co., LTD.

https://sinsin2002.tradekorea.com/

Sinsin Pharmaceutical Co., Ltd. is a pharmaceutical company that specializes in the development, manufacturing, and marketing of over-the-counter (OTC) medicines for external use. The company's core product portfolio centers on topical anti-inflammatory and analgesic drugs, including its widely recognized brand of pain relief patches, "SINSIN PAS," alongside various sprays and lotions. The company also produces a diverse range of consumer healthcare items such as mosquito repellents, wound care products like surgical plasters and healing bands, anti-mycotic treatments, and other dermatological preparations for both domestic and overseas markets.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획자진취하등) (과민성 방광 치료제 UIP620의 제3상 임상시험 조기종료)
Regulatory Filings Classification · 80% confidence The document is a timely disclosure from a Korean issuer (KRX) regarding voluntary withdrawal and early termination of a Phase III clinical trial, containing details of the trial set-up and rationale. It is not a standalone financial report, earnings release, dividend notice, or M&A/board change. It is a general regulatory announcement of a material event (“투자판단 관련 주요경영사항”), falling under the fallback category for miscellaneous regulatory filings.
2026-05-22 Korean
투자판단관련주요경영사항(임상시험계획자진취하등) (불면증 환자의 단기치료제 SS262의 제1상 임상시험 조기종료)
Regulatory Filings Classification · 90% confidence The document is a Korean corporate disclosure titled “투자판단 관련 주요경영사항” reporting the voluntary early termination of a Phase 1 clinical trial for drug SS262. It contains no financial statements, earnings figures, board changes, dividends, or share transactions. It is a material management announcement required by regulators rather than a full report, results announcement, or proxy material. None of the specific categories (ER, IR, 10-K, CT, etc.) fit; it is best classified as a general regulatory filing (RNS).
2026-05-22 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is a 분기보고서 (quarterly report) for the period January 1, 2026 to March 31, 2026 with detailed financial statements, segment data, operating performance, risk disclosures, and management overview. It is a comprehensive interim report containing actual financial data rather than an announcement of publication or a summary. Therefore, it fits the “Interim / Quarterly Report” category. Q1 2026
2026-05-15 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a brief announcement about a change in the company's classification or department within an exchange or regulatory framework, specifically a change from '중견기업부' (mid-sized enterprise section) to '우량기업부' (excellent enterprise section). It does not contain financial data, management changes, or detailed reports. This type of announcement fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about company classification change.
2026-04-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document presents the detailed outcomes of agenda items at the regular shareholders’ meeting: approval of financial statements, dividend resolutions, director elections, voting record date and vote counts/percentages for each proposal. This is a declaration of voting results from the AGM, matching the Declaration of Voting Results & Voting Rights Announcement category.
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Shinshin Pharmaceutical. It contains key financial data, audit opinions (unqualified/appropriate), and financial statements for the fiscal year ending 2025-12-31. While it summarizes financial results, it is specifically categorized as an audit report submission under Korean regulatory filing standards, which aligns with the 'AR' (Audit Report / Information) category. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.